Nemesis Bioscience today announced the appointment of Dr Mark McCamish as Scientific Advisor for the development of its suite of Bacterial Cybergenetics© technologies. These include Nemesis Symbiotics© for applications including the reversal of antibiotic resistance and Transmids© for their clinical, veterinary and industrial delivery. Mark, an investor in Nemesis, is currently President and CEO of Forty

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000, and the commencement of

Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment is effective from the 1st July and will bring Alastair’s

Nemesis Bioscience has beaten tough competition from across the country to win a place to showcase its product at the UK’s largest innovation show in

Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has received a funding award from the UK’s innovation agency, Innovate UK. The Smart Award will

Nemesis Bioscience Ltd has raised £300,000 in seed funding from Angel investors and from Finance Wales to extend the application of its proprietary biological therapeutics

Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has been awarded an Entrepreneurship Award by King’s College, Cambridge. The King’s College judges, who include